DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/24/2026 has been entered.
Response to Amendment
The amendment filed on 8/24/2026 has been entered. Claims 1-21 are pending in the application. Claims 3-5, 8-10, and 13-19 remain withdrawn.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-2, 6-7, 11-12, and 20-21 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Mojarrad et al. (US 2022/0288305 A1).
Regarding claim 1, Mojarrad discloses an auto-injector (drug delivery device 10) for administering a beneficial agent (drug 102) (see Figs. 1-2, par. [0026] and [0028]), the auto-injector (drug delivery device 10) comprising:
a pressure chamber (pressure chamber 100) defined by a pressure chamber wall (wall 101) (see Figs. 1-2, par. [0027] and [0042]), and the pressure chamber wall (wall 101) configured to define a boundary of the pressure chamber (wall 101) (see Figs. 1-2, par. [0042]);
a primary container (container 110) comprising a sidewall (wall 112), a stopper (plunger 120), an inner surface (interior surface 112a), and an outlet (distal/right opening of container 110), the sidewall (wall 112) defining a longitudinal axis (axis A) (see Figs. 1-2, par. [0027]-[0028], [0040]), the primary container (container 110) being completely housed within the pressure chamber (pressure chamber 100) with an entirety of the sidewall (wall 112) of the primary container (container 110) within the boundary of the pressure chamber (pressure chamber 100) (see Figs. 1-2, par. [0006] and [0042]), the sidewall (wall 112) and the pressure chamber (pressure chamber 100) being in fixed position relative to one another (see Figs. 1-2, par. [0040]), the sidewall (wall 112) of the primary container (container 110) forming no portion of the boundary of the pressure chamber (pressure chamber 100) (see Figs. 1-2, par. [0006] and [0042]), the entirety of the sidewall (wall 112) configured to receive a balanced pressure exposure within the pressure chamber (pressure chamber 100) (see Figs. 1-2, par. [0042]), the stopper (plunger 120) being disposed relative to the inner surface (interior surface 112a) and sealingly engaged to the inner surface (interior surface 112a) and movable along the longitudinal axis (axis A) (see Figs. 1-2, par. [0027]-[0028] and [0040]), the primary container (container 110) further comprising a containment volume (reservoir 114) defined by the stopper (plunger 120) and the inner surface (interior surface 112a) (see Figs. 1-2, par. [0028]);
an administration device (container access mechanism 130) aligned with the longitudinal axis (axis A) and configured to establish fluid communication with the containment volume (reservoir 114) through the outlet (distal/right opening of container 110) (see Figs. 1-2, par. [0032]);
wherein an increase in a pressure within the pressure chamber (pressure chamber 100) increases the pressure within the containment volume (reservoir 114) such that the stopper (plunger 120) moves along the longitudinal axis (axis A) relative to the inner surface (interior surface 112a) to reduce the containment volume (reservoir 114) and to expel the beneficial agent (drug 102) through the administration device (container access mechanism 130) along the longitudinal axis (axis A) in the same direction as travel of the stopper (plunger 120) (see Figs. 1-4, par. [0032], [0035], [0042], [0044]-[0045]).
Regarding claim 2, Mojarrad discloses the auto-injector of claim 1, wherein the primary container (container 110) is disposed concentrically within the pressure chamber (pressure chamber 100) about the longitudinal axis (axis A) (see Figs. 1-4).
Regarding claim 6, Mojarrad discloses the auto-injector of claim 1, further comprising:
an energy source (actuator 16 and mechanical or electrical means, see par. [0031]-[0035]) selectively activatable to increase the pressure within the pressure chamber (pressure chamber 100) upon activation (see Figs. 1-2, par. [0031]-[0035]).
Regarding claim 7, Mojarrad discloses the auto-injector of claim 6, wherein the pressure within the pressure chamber (pressure chamber 100) equals the pressure within the containment volume (reservoir 114) (see Figs. 1-2, par. [0035] and [0042]).
Regarding claim 11, Mojarrad discloses the auto-injector of claim 6, wherein the energy source (actuator 16 and mechanical or electrical means, see par. [0031]-[0035]) comprises one of compressed gas or liquefied gas (see par. [0034]-[0035]).
Regarding claim 12, Mojarrad discloses the auto-injector of claim 1, wherein the administration device (container access mechanism 130) is one of a needle, a dispenser, or a connector (see Figs. 1-4, [0032]-[0033], [0044]-[0045], container access mechanism 130 includes a container needle 132; container access mechanism 130 dispenses drug 102 from container 110 into fluid conduit 18; container access mechanism 130 connects to container 110 and fluid conduit 18).
Regarding claim 20, Mojarrad discloses the auto-injector of claim 1, wherein the increase in the pressure within the pressure chamber (pressure chamber 100) acts upon an exterior surface (second end 120b) of the stopper (plunger 120) to increase the pressure within the containment volume (reservoir 114) (see Figs. 1-2, par. [0028], [0035], and [0042]).
Regarding claim 21, Mojarrad discloses the auto-injector of claim 1, further comprising:
the containment volume (reservoir 114) comprising the beneficial agent (drug 102) such that reduction of the containment volume (reservoir 114) expels the beneficial agent (drug 102) (see Figs. 1-2, par. [0035] and [0042]).
Response to Arguments
Applicant's arguments filed 8/24/2026 have been fully considered but they are not persuasive.
In regards to independent claim 1, Applicant argues that Mojarrad does not disclose an administration device aligned with an axis of the sidewall. This argument is not found to be persuasive. In the rejection of claim 1 above, the Examiner interprets that container access mechanism 130 of Mojarrad corresponds to the claimed administration device. Figures 1-2 clearly show that container access mechanism 130 is aligned with axis A. Thus, this interpretation of Mojarrad appears to teach an administration device aligned with an axis of the sidewall in the manner currently recited in claim 1. Applicant’s argument that needle insertion mechanism 20 must be considered the claimed “administration mechanism” is not found to be persuasive because the claim language does not require the administration mechanism to be the structure which pierces into the patient’s skin.
In regards to independent claim 1, Applicant further argues that Mojarrad does not disclose expulsion along the longitudinal axis in the same direction as travel of the stopper. This argument is not found to be persuasive. Plunger 120 (corresponding to the claimed stopper) expels the drug 102 in a direction from the second end 110b of the container 110 to the first end 110a of the container 110 (see Figs. 1-4, par. [0035], [0040], [0044]-[0045]). As shown in Figs. 1-4, plunger 120 moves along the axis A. The drug 102 travels through container access mechanism 130 in the same (left to right) direction as the plunger 120 (see Figs. 1-4, par. [0032], [0035], [0042], [0044]-[0045]). Therefore, Mojarrad appears to teach this limitation as currently recited in the claim.
In regards to dependent claim 2, Applicant argues that Mojarrad does not disclose the primary container disposed concentrically within the pressure chamber about the longitudinal axis. This argument is not found to be persuasive. Container 110 is concentric within the pressure chamber 100 about axis A as shown in Figs. 1-4. Therefore, Mojarrad appears to teach this limitation as currently recited in the claim.
Conclusion
Any inquiry concerning this communication or earlier communications from th examiner should be directed to AVERY SMALE whose telephone number is (571)270-7172. The examiner can normally be reached Mon.-Fri. 8-4 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached at (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/AVERY SMALE/Examiner, Art Unit 3783
/KAMI A BOSWORTH/Primary Examiner, Art Unit 3783